Clinical Trial Detail

NCT ID NCT02935790
Title Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acetylon Pharmaceuticals Incorporated
Indications

melanoma

Therapies

Citarinostat + Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.